Mateon Therapeutics is developing antisense oligonucleotides for the treatment of coronavirus infectious disease (COVID-2019) as well as other viral diseases occurring due to zoonotic viruses; under a rapid antiviral response programme. The company will develop the therapeutics using its artificial intelligence platform; EdgePoint which processes machine learning models. Early research is underway in the US.
The antisense programme which is being developed under Rapid Antiviral Response Program will be modeled after the ongoing EdgePoint AI development model at Mateon. After developing and establishing the technology, Mateon plans to form a separate company or sell the technology and the programme to a larger entity for further development.
Key Development Milestones
In March 2020, Mateon Therapeutics reported that it is evaluating the potential of its AI Vision technology to help monitor patients infected with the COVID-19 virus, or any other viruses. Mateon Therapeutics reported that its two additional therapeutic oligonucleotides designed to target COVID-19, demonstrated potent antiviral activity. These candidates were all designed to work synergistically to avoid resistant mutations frequently seen with viral infections. They inhibited virus binding to its target, thereby stopping the virus from replicating itself and stopping viral induced pneumonia, which often leads to patient complications   .